Dexcel Pharma
CVC
Active
Or Akiva, Israel
7
120M
4
0.13
1
0.43
- Areas of investment
Summary
In 1968 was created Dexcel Pharma, which is appeared as Corporate Investor. The venture was found in Asia in Israel. The leading representative office of defined Corporate Investor is situated in the Jerusalem.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Dexcel Pharma, startups are often financed by Viking Global Investors, SoftBank Investment Advisers, QVT Financial. The meaningful sponsors for the fund in investment in the same round are QVT Financial, Viking Global Investors, SoftBank Investment Advisers. In the next rounds fund is usually obtained by Viking Global Investors, SoftBank Investment Advisers, Founders Fund.
The fund was created by Dan Oren. The overall number of key employees were 1.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular fund investment industries, there are Biopharma, Health Care. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Roivant Sciences
Deals in the range of more than 100 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. When the investment is from Dexcel Pharma the average startup value is more than 1 billion dollars. The important activity for fund was in 2014.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 7
- Lead investments
- 1
- Rounds per year
- 0.13
- Follow on index
- 0.43
- Investments by industry
- Biotechnology (6)
- Life Science (3)
- Product Research (2)
- Biopharma (2)
- Pharmaceutical (2) Show 6 more
- Investments by region
-
- United States (6)
- Israel (1)
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 1B
- Group Appearance index
- 1.00
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Kriya Therapeutics | 16 May 2022 | Biotechnology, Life Science | Late Stage Venture | 270M | United States, California, Palo Alto |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.